New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:15 EDTTKMR, GSK, NNVC, BCRXWHO says ethical to offer unproven interventions in light of Ebola outbreak
The World Health Organization issued a statement that read in part: "West Africa is experiencing the largest, most severe and most complex outbreak of Ebola virus disease in history. Ebola outbreaks can be contained using available interventions like early detection and isolation, contact tracing and monitoring, and adherence to rigorous procedures of infection control. However, a specific treatment or vaccine would be a potent asset to counter the virus...In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention." Publicly traded companies that have confirmed development activities on Ebola treatments include Tekmira Pharmaceuticals (TKMR), GlaxoSmithKline (GSK), NanoViricides (NNVC) and BioCryst (BCRX). Reference Link
News For TKMR;GSK;NNVC;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
14:43 EDTGSKTheravance drops after partner announces restructuring, posts abstracts
Shares of Theravance, (THRX) a biopharmaceutical company that has economic ties to GlaxoSmithKline (GSK), are lower in afternoon trading after Glaxo reported restructuring plans. Additionally, Theravance disclosed last night that GSK is scheduled to present data from Phase 3 studies at an upcoming medical conference. CHEST 2014 in Austin, Texas, to be held from October 25-30. WHAT'S NEW: Earlier today, GlaxoSmithKline announced it intends to refocus its global pharmaceuticals business and cost base following the divestment of its oncology products and the changed dynamics now faced in the U.S. respiratory market. Theravance has strategic alliances with GlaxoSmithKline in respiratory products. Also, Theravance disclosed last night that Glaxo is scheduled to present data from Phase 3 studies at CHEST 2014, which is being held from October 25-30. Umeclidinium/Vilanterol, a once-daily combination treatment comprising two bronchodilators in Theravance's ELLIPTA inhaler, and Fluticasone Furoate/Vilanterol, a once-daily combination of a LABA and inhaled corticosteroid, have been developed under a collaboration pact between Glaxo and Theravance. Abstracts of the planned oral presentations can be found in the CHEST Journal, Theravance noted in its filing. PRICE ACTION: In afternoon trading, shares of Theravance fell 10.25% to $16.73.
09:21 EDTGSKOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Dow Chemical (DOW), up 3.7%... iRobot (IRBT), up 12%... Six Flags (SIX), up 13%... GlaxoSmithKline (GSK), up 2%... Broadcom (BRCM), up 7%... Boston Scientific (BSX), up 4.3%... Abbott (ABT), up 1.8%... Yahoo! (YHOO), up 6%. ALSO HIGHER: Blue Earth (BBLU), up 26.4% after CEO says statements in Seeking Alpha blog are "false and misleading."... GW Pharmaceuticals (GWPH), up 5.4% after Epidiolex receives orphan designation from EMA. DOWN AFTER EARNINGS: 3D Systems (DDD), down 15%... Biogen (BIIB), down 7%... Lumber Liquidators (LL), down 13.4%... Norfolk Southern (NSC), down 3%... Angie's List (ANGI), down 8.8%. ALSO LOWER: Nanosphere (NSPH), down 33% after filing secondary, reporting preliminary Q3 revenue... Himax Technologies (HIMX), down 16% after announcing that Google (GOOG) will not exercise an additional investment option in the company... Cree (CREE), down 10.5%, downgraded at DA Davidson and Canaccord following the company's Q1 earnings results... Ocwen Financial (OCN), down 7% after downgraded to Hold at Evercore, downgraded to Neutral at BofA Merrill Lynch... VMware (VMW), down 7.8%, downgraded at Nomura and Raymond James following the company's Q3 results.
07:49 EDTGSKGlaxoSmithKline sees FY14 dividend to rise 3% to 80p, 2015 dividend flat
Subscribe for More Information
07:48 EDTGSKGlaxoSmithKline announces restructuring program for pharmaceuticals business
Subscribe for More Information
07:46 EDTGSKGlaxoSmithKline to explore IPO of minority shareholding in ViiV Healthcare
Glaxo announced "further significant steps" within its Pharmaceuticals business to realize value for shareholders and deliver improved operational performance. Glaxo stated: "Five years ago, we created ViiV Healthcare, a new standalone global business focused on development of treatments for HIV. This has been a highly innovative and successful venture with our equity partners Pfizer and Shionogi. The business has made very significant progress in both R&D and commercial execution, culminating in the recent successful launches of Tivicay and Triumeq. We believe now is the right time to explore the potential for an IPO of a minority shareholding in this business. This will provide greater visibility of the intrinsic value we see in its currently marketed assets and future pipeline and also enhance potential future strategic flexibility."
07:44 EDTGSKGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
07:42 EDTGSKGlaxoSmithKline reports Q3 core EPS 27.9p, up 5% CER ex-divestments
Subscribe for More Information
06:41 EDTBCRX, TKMR, GSKWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
October 21, 2014
19:53 EDTTKMRTekmira commences limited GMP manufacture of Ebola drug
Tekmira Pharmaceuticals provided an update on its Ebola program. The company is reporting it has commenced limited GMP manufacture of a new therapeutic specifically targeting the Ebola, Guinea variant, which is the viral variant responsible for the Ebola epidemic currently prevalent in West Africa. Supply of this new product will be available in early December, for potential use by various collaborators. The Company has completed the design of a modified RNAi therapeutic specifically targeting the Ebola viral variant, now termed 'Ebola-Guinea.' The company's IND for TKM-Ebola remains on partial clinical hold with respect to the multiple ascending dosing in healthy subjects. The company expects this matter to be resolved this quarter.
11:04 EDTGSKGlaxoSmithKline receives orphan status for dabrafenib
The FDA granted GlaxoSmithKline orphan status for dabrafenib, its possible treatment of patients with BRAF mutation positive non-small cell lung cancer.
09:48 EDTTKMRShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
07:21 EDTTKMRiBio valuation will be hard to maintain, TheStreet's Feuerstein says
iBio's current valuation will be hard to maintain "even under the best Ebola stockpiling scenario," TheStreet's Adam Feuerstein argues. He notes Ebola related stocks fell yesterday after the quarantines related to Thomas Duncan ended. Reference Link
07:06 EDTGSKFierce Biotech to hold a breakfast meeting
Subscribe for More Information
October 20, 2014
09:09 EDTBCRX, TKMR, GSKEMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
07:19 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
October 19, 2014
16:44 EDTTKMR, BCRXEbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTTKMR, BCRXCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTBCRX, GSK, TKMRBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
11:17 EDTGSKGSK says Ebola vaccine too late for current epidemic, BBC reports
Subscribe for More Information
09:46 EDTBCRX, TKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use